Edratide

DB15272InvestigationalSmall molecule

Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).

Formula / weight: C₁₁₁H₁₄₉N₂₇O₂₈ · 2309.574 g/mol (avg)

Resolves to

Compound

UNII38PLP07BKCCAS433922-67-9

Structure

InChIKeyVXXZQHUWZSRPAM-CDJUQFLLSA-NSMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)CN)[C@@H](C)CC)C(=O)NCC(O)=O

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of Edratide, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account